BMS, AbbVie nab 'breakthrough' tag for multiple myeloma-fighting antibody

A new drug for blood cancer from Bristol-Myers Squibb ($BMY) and AbbVie ($ABBV) is on the fast track to FDA approval, winning a priority review to treat multiple myeloma. Report